PL2124925T3 - Kompozycja użyteczna w leczeniu cukrzycy typu 2 - Google Patents

Kompozycja użyteczna w leczeniu cukrzycy typu 2

Info

Publication number
PL2124925T3
PL2124925T3 PL07847224T PL07847224T PL2124925T3 PL 2124925 T3 PL2124925 T3 PL 2124925T3 PL 07847224 T PL07847224 T PL 07847224T PL 07847224 T PL07847224 T PL 07847224T PL 2124925 T3 PL2124925 T3 PL 2124925T3
Authority
PL
Poland
Prior art keywords
diabetes
treatment
type
composition useful
useful
Prior art date
Application number
PL07847224T
Other languages
English (en)
Inventor
Franco Gaetani
Ashraf Virmani
Original Assignee
Alfasigma S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma S.P.A. filed Critical Alfasigma S.P.A.
Publication of PL2124925T3 publication Critical patent/PL2124925T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL07847224T 2007-02-27 2007-11-20 Kompozycja użyteczna w leczeniu cukrzycy typu 2 PL2124925T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07103137 2007-02-27
PCT/EP2007/062545 WO2008104239A1 (en) 2007-02-27 2007-11-20 Composition useful for the treatment of type 2 diabetes
EP07847224.8A EP2124925B1 (en) 2007-02-27 2007-11-20 Composition useful for the treatment of type 2 diabetes

Publications (1)

Publication Number Publication Date
PL2124925T3 true PL2124925T3 (pl) 2018-09-28

Family

ID=38093451

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07847224T PL2124925T3 (pl) 2007-02-27 2007-11-20 Kompozycja użyteczna w leczeniu cukrzycy typu 2

Country Status (17)

Country Link
US (2) US20100029759A1 (pl)
EP (1) EP2124925B1 (pl)
JP (2) JP5697337B2 (pl)
KR (1) KR101699430B1 (pl)
CN (1) CN101616665B (pl)
AU (1) AU2007348123B2 (pl)
BR (1) BRPI0721333A8 (pl)
CA (1) CA2678746C (pl)
EA (1) EA016855B1 (pl)
ES (1) ES2676529T3 (pl)
HK (1) HK1135030A1 (pl)
IL (1) IL200192A (pl)
MX (1) MX2009008873A (pl)
PL (1) PL2124925T3 (pl)
PT (1) PT2124925T (pl)
SG (1) SG177993A1 (pl)
WO (1) WO2008104239A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2124925B1 (en) * 2007-02-27 2018-06-27 Alfasigma S.p.A. Composition useful for the treatment of type 2 diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
US20020061301A1 (en) * 1998-05-15 2002-05-23 Olga Bandman Human carbohydrate metabolism enzymes
CA2375378C (en) * 1999-06-08 2009-08-11 Arduino Arduini Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
US6245800B1 (en) * 1999-06-08 2001-06-12 Sigma-Tau Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
US20080102138A1 (en) * 2006-06-21 2008-05-01 Bieley Harlan C Replacement of Vitamins, Minerals and Neurotransmitter Losses from Tobacco Smoking
EP2124925B1 (en) * 2007-02-27 2018-06-27 Alfasigma S.p.A. Composition useful for the treatment of type 2 diabetes

Also Published As

Publication number Publication date
EP2124925A1 (en) 2009-12-02
EA016855B1 (ru) 2012-08-30
JP2010519333A (ja) 2010-06-03
CN101616665B (zh) 2013-03-27
HK1135030A1 (en) 2010-05-28
CN101616665A (zh) 2009-12-30
JP5697337B2 (ja) 2015-04-08
MX2009008873A (es) 2009-08-28
WO2008104239A1 (en) 2008-09-04
AU2007348123A1 (en) 2008-09-04
CA2678746C (en) 2018-05-01
ES2676529T3 (es) 2018-07-20
PT2124925T (pt) 2018-07-12
KR20090115939A (ko) 2009-11-10
CA2678746A1 (en) 2008-09-04
EA200970798A1 (ru) 2010-04-30
EP2124925B1 (en) 2018-06-27
US20150045424A1 (en) 2015-02-12
IL200192A (en) 2015-06-30
KR101699430B1 (ko) 2017-01-24
IL200192A0 (en) 2010-04-15
AU2007348123B2 (en) 2013-01-17
SG177993A1 (en) 2012-02-28
JP2014040442A (ja) 2014-03-06
BRPI0721333A2 (pt) 2014-02-25
BRPI0721333A8 (pt) 2017-12-26
US20100029759A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
ZA200902374B (en) Compositions useful for the treatment of diabetes
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
HK1148435A1 (en) Oxadiazoanthracene compounds for the treatment of diabetes
PL1975226T3 (pl) Płynna kompozycja do obróbki
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP2201370A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL195203A0 (en) Compounds for the treatment of metabolic disorders
IL192852A0 (en) Compounds for the treatment of metabolic disorders
GB0909297D0 (en) Composition for the treatment of skin conditions
HK1156844A1 (en) Pharmaceutical composition 271 271
IL201119A0 (en) Methods and compositions of derivatives of probucol for the treatment of diabetes
IL192851A0 (en) Compounds for the treatment of metabolic disorders
IL195392A0 (en) Compounds for the treatment of metabolic disorders
IL200192A0 (en) Composition useful for the treatment of type 2 diabetes
PL2252302T3 (pl) Kompozycja do leczenia zapalenia kości i stawów
EP2331099A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS
HU0500947D0 (en) Composition for treatment of paradontosis
ZA200807156B (en) Liquid treatment composition
IL192982A0 (en) Compounds for the treatment of metabolic disorders
IL184620A0 (en) Composition for the treatment of inflammation
HUP0500948A2 (en) Composition for treatment of diabeticus paradontosis
GB0705674D0 (en) Composition for the treatment of halitosis
AP2008004391A0 (en) Pharmaceutical composition suitable for the treatment of malaris within one day
SI2271321T1 (sl) Farmacevtski sestavek 271